Dr. Pan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1580 Commanche Ave
Green Bay, WI 54313Phone+1 920-635-8326Fax+1 920-430-4659
Summary
- Dr. Charlie Pan is a radiation oncologist in Green Bay, WI and is affiliated with Bellin Hospital. He received his medical degree from University at Buffalo School of Medicine and has been in practice 18 years. He is experienced in stereotactic radiosurgery, intensity-modulated radiation therapy, radiosurgery, head and neck radiation oncology, and stereotactic body radiotherapy. He has more than 20 publications and over 500 citings.
Education & Training
University of MichiganResidency, Radiation Oncology, 2000 - 2004
Trinity Health Ann Arbor HospitalInternship, Internal Medicine, 1999 - 2000
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1999
Certifications & Licensure
MI State Medical License 1999 - 2026
WI State Medical License 2010 - 2025- American Board of Radiology Radiation Oncology
Clinical Trials
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate Cancer Start of enrollment: 2008 Feb 01
- Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer Start of enrollment: 2009 Sep 01
Publications & Presentations
PubMed
- 3 citationsImpact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.Daniel A. Hamstra, Kyounghwa Bae, Gerald E. Hanks, Chen Hu, William U. Shipley
Cancer. 2015-03-15 - 24 citationsPre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancerBryan J. Schneider, J. Lee, James A. Hayman, Andrew C. Chang, Mark B. Orringer
Investigational New Drugs. 2013-04-01 - 53 citationsPrediction of liver function by using magnetic resonance-based portal venous perfusion imaging.Yue Cao, Hesheng Wang, Timothy D. Johnson, Charlie Pan, Hero K. Hussain
International Journal of Radiation Oncology, Biology, Physics. 2013-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
